Table 1 Characteristics of patients enrolled in the study
Patient ID | Sex | Age | Mutationa | Disease sites | Stage IV subcategory | Best response (RECIST) | EP | Progression sites | Survival status | Number of samples |
---|---|---|---|---|---|---|---|---|---|---|
1 | F | 75 | p.V600E | Brain, lymph nodes, lung | M1d | PR | N | Brain | Dead | 3 |
3 | F | 81 | p.V600K | Liver | M1c | SD | N | Liver | Dead | 3 |
6 | F | 42 | p.V600E | Peritoneum | M1c | PR | N | Peritoneum | Dead | 4 |
8 | M | 85 | p.V600E | Brain, liver, lymph nodes, lung | M1d | PR | N | Brain, lung, soft tissues, lymph nodes | Dead | 3 |
9 | F | 37 | p.V600E | Soft tissue, lymph nodes, liver, adrenal gland, bones, peritoneum | M1c | PR | N | Soft tissues, liver, heart | Dead | 4 |
10 | F | 65 | p.V600Kb | Brain, lymph nodes, lung, liver | M1d | PR | N | Brain | Dead | 4 |
12 | M | 59 | p.V600E | Lymph nodes | M1a | CR (SR) | N | NA | Alive | 3 |
13 | F | 42 | p.V600E | Brain, peritoneum, lymph nodes, liver, soft tissues, lung, adrenal gland | M1d | PR | Y | Brain | Dead | 4c |
15 | F | 46 | p.V600Eb | Lung, bones | M1c | PR (SR) | N | NA | Alive | 3 |
17 | M | 48 | p.V600E | Soft tissues, thoracic wall, bones, subcutaneous, abdominal wall | M1c | CR | Y | Bones, soft tissues, peritoneum, lung | Dead | 2 |
19 | M | 64 | p.V600E | Lung, lymph nodes | M1b | PD | Y | Brain, lung, spleen, lymph nodes | Dead | 2 |
24 | M | 51 | p.V600Eb | Tonsils, lymph nodes | M1c | CR (SR) | N | NA | Alive | 3 |
27 | M | 85 | p.V600K | Lymph nodes, liver | M1c | PR | N | Liver, lung, adrenal gland, spleen | Dead | 4 |
28 | M | 84 | p.V600E | Subcutaneous, lymph nodes, liver, bones | M1c | PR | N | Adrenal gland, brain | Dead | 3 |
34 | F | 75 | p.V600Kb | Lung | M1b | PD | Y | Peritoneum, lung | Dead | 1 |
48 | M | 59 | p.T599dup | Pleura, lung, lymph nodes | M1b | PR | N | Pleura, liver, lymph nodes, brain | Alive | 3 |
49 | M | 64 | p.V600E | Brain, liver, lung, lymph nodes, bones | M1d | PD | Y | Brain | Dead | 1 |